USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: ARISAPH PHARMACEUTICALS, INC.
City: BOSTON
State: MA
Zip+4: 02110-2321
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
STTR Phase I $745,131.00 3

Award List:

A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors

Award Year / Program / Phase: 2011 / STTR / Phase I
Agency: HHS
Research Institution: FOX CHASE CANCER CENTER
Principal Investigator: Barry Jones – 617-986-4500
Award Amount: $245,638.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Cancer is America's second leading cause of death. Many approved cancer drugs, such as bortezomib (Velcade), are cytotoxic agents that kill normal cells as well as tumor cells. Therapeutic benefit depends on tumor cellsbeing more sensitive than normal cells,… More

A Small Molecule to Activate Cetuximab to Kill K-RAS Mutant Colorectal Tumors

Award Year / Program / Phase: 2012 / STTR / Phase I
Agency: HHS
Research Institution: TUFTS UNIVERSITY BOSTON
Principal Investigator: Barry Jones – 617-986-4500
Award Amount: $266,641.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): In the United States colorectal cancer (CRC) is the third leading cause of cancer mortality. Surgery is the primary treatment for early stage CRC; but adjuvant therapy is usually needed in advanced disease. Approximately 55% of CRC patients have metastatic… More

A Small Molecule to Activate Tumor Immunity after PLX403 in V600E BRAF Melanoma

Award Year / Program / Phase: 2013 / STTR / Phase I
Agency: HHS
Research Institution: TUFTS UNIVERSITY
Principal Investigator: Barry Jones – 617-763-9175
Award Amount: $232,852.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): In the United States, around 76,250 new cases of melanoma and 9,180 melanoma-related deaths are predicted for 2012. With the therapeutic options currently available, metastatic melanoma patients face the bleak prospectof at best, 10 month's survival and a… More